Adjuvant therapy with trastuzumab (Herceptin®) in primary breast cancer;Adjuvanter einsatz von trastuzumab (Herceptin®) beim primären mammakarzinom - Aktuelle datenlage und bewertung der stellungnahme des kompetenz centrums onkologie des MDK Nordrhein

Zentralblatt fur Gynakologie

Volumn 128, Issue 1, 2006, Pages 30-37

  Huober, Jens ^a,c   Jackisch, C ^b   Mobus V ^d   Wallwiener, D ^a   Kaufmann, M ^d   Von Minkwitz, C ^d,e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Klinikum Offenbach   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e GERMAN BREAST GROUP   (Germany)

Author keywords

Adjuvant therapy; Breast cancer; Herceptin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MULTICENTER STUDIES; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS;

EID: 32644436277     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-921382     Document Type: Review

References (10)

1. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomised trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3682
2. Cuzick C. Forest plots and the interpretation of subgroups. Lancet 2005; 365: 1308
3. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717
4. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2005; 16: 1569-1583
5. Heyll A, Zimmer B. Stellunghnahme des KC Onkologie, Version 28.10.2005. www.kconkologie.de
6. Perez E, Suman VJ, Davidson N, Martino S, Kaufmann P. NCCTG update. ASCO, Scientific session, Mai 16, 2005
7. Piccart-Gebhart M, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N Engl J Med 2005; 253: 1659-1672
8. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for Operable Her-2 Positive Breast Cancer. N Engl J Med 2005; 353: 1673-1684
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001; 344: 783-792
10. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP-B31. J Clin Oncol 2005; 23: 7811-7819